Levothyroxine Sodium Tablets Recalled Due to Potency Failures
Viatris Inc is recalling 35,883 bottles of Levothyroxine Sodium Tablets (112 mcg) distributed nationwide due to potency failures. Some tablets contain too much active ingredient (superpotent) and others too little (subpotent). No illnesses have been reported.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This FDA Class II recall involves a risk-of-harm product (potency failures in thyroid hormone replacement) where no illnesses or injuries have been reported. Levothyroxine dosing requires precision to maintain proper thyroid function.
Plain-English summary
Viatris Inc is recalling Levothyroxine Sodium Tablets USP, 112 mcg, packaged in both 90-count bottles (NDC 0378-1811-77) and 1000-count bottles (NDC 0378-1811-10). Approximately 35,883 bottles have been distributed nationwide in the United States and Puerto Rico. The recall affects five specific lots: 8171623 (90-count, expiration Feb 2025), 8164486 (90-count, expiration Nov 2024), 3205462 (1000-count, expiration Aug 2025), 3192428 (1000-count, expiration Feb 2025), and 3184096 (1000-count, expiration Nov 2024).
The recall was initiated due to potency failures discovered in the product. Some tablets in the affected lots contain more active ingredient than intended (superpotent), while others contain less (subpotent). These potency failures could affect the therapeutic effectiveness of the medication.
This recall affects patients taking Levothyroxine Sodium Tablets from the identified lot numbers and expiration dates. Levothyroxine is a commonly prescribed thyroid hormone replacement medication. Patients should verify whether their medication is from an affected lot by checking the lot number and expiration date on their prescription bottle. Consumers who believe they may have affected product should consult with their pharmacist or healthcare provider.
The recalled product
- Product
- LEVOTHYROXINE SODIUM (LEVOTHYROXINE SODIUM)
- Brand
- LEVOTHYROXINE SODIUM
- Manufacturer
- Viatris Inc
- Hazard
- super-potent
- sub-potent
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (8)
- Lot #: a) 8171623
- Exp. Date Feb 2025
- 8164486
- Exp. Date Nov 2024 b)3205462
- Exp. Date Aug 2025
- 3192428
- 3184096
- Exp. Date Nov 2024
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · LEVOTHYROXINE SODIUM
- HighLevothyroxine Sodium Tablets Recalled for Out-of-Specification Potency
FDA (Drugs) · 2025-03-26
- HighFDA Recalls Super-Potent Levothyroxine Sodium Tablets Due to Potency Deviation
FDA (Drugs) · 2025-03-26
- HighLevothyroxine Sodium tablets recalled for impurity specification failure
FDA (Drugs) · 2025-01-08
- HighLevothyroxine sodium tablets recalled for potency failures nationwide
FDA (Drugs) · 2024-12-18
- HighFDA Recalls Levothyroxine Sodium Tablets for Potency Variation
FDA (Drugs) · 2024-12-18
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- SevereErythromycin Tablets Recalled for Impurity Above Acceptable Limits
FDA (Drugs) · 2026-05-27
- SevereAtomoxetine Capsules Recalled Due to Labeling Mix-Up Error
FDA (Drugs) · 2026-05-27
- ModeratePrimidone Tablets Recalled Due to API Cross-Contamination
FDA (Drugs) · 2026-05-27
- SevereMG217 Multi-Symptom Treatment Cream recalled for microbial contamination
FDA (Drugs) · 2026-05-27